Biotech Values

[DewDiligence]

Teva acquires (private) Labrys Biologics for $200M up-front plus $625M in contingent (pre-commercial) milestones:

http://www.sec.gov/Archives/edgar/data/818686/000130901414000383/exhibit1.htm

Labrys is developing LBR-101, a fully humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) currently in Phase IIb clinical trials for prevention of chronic and episodic migraine.

…Potential peak sales for LBR-101 are estimated to reach $2 to $3 billion.

…With the goal of becoming a global leader in pain by 2020, the Labrys acquisition adds a significant migraine prophylaxis dimension to Teva’s extensive pain care franchise, which includes a range of investigational, approved and marketed treatments for migraine, cancer pain and chronic pain.

p.s. The Haaretz article you posted regarding Teva’s organizational restructuring requires a subscription to read.